Brind.
  1. Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.

Eli Lilly and Novo Nordisk faced market pressure from federal policy, while the CalRx program funded Civica for production runs.

2 reports, 2 independent Updated Aug 18
Gone quiet
Reports
2
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Eli Lilly and Novo Nordisk faced market pressure from federal policy, while the CalRx program funded Civica for production runs.

Who's involved

What this event is mainly about
Eli Lilly and CompanyNovo Nordisk

How it developed

Newest first. Tap a step to see who reported it.
  1. Walgreens is serving as a distribution point for the state's CalRx insulin glargine program, while Civica handles the manufacturing of the biosimilar insulin.Sub-event
  2. CalRx program funded Civica for production runs amid market pressure on Lilly and Novo Nordisk.1 source

Keep exploring

Part of

Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.

Also in this story

All 5 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped